Jonsson Comprehensive Cancer Center
🇺🇸United States
The Biodistribution of 1-[2 Deoxy-2, -18 Fluroarabinfuranosyl]Cytosine [18FAC] in Healthy Subjects and Patients With Cancer, Autoimmune/Inflammatory Diseases
Completed
- Conditions
- CancerInflammation
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT01180907
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
The Biodistribution of 1-L-(2 Deoxy-2,- 18 Fluoroarabinofuranosyl) Cytosine ([18F]L-FAC) in Healthy Subjects and Patients With Cancer, Autoimmune and Inflammatory Diseases
Completed
- Conditions
- Autoimmune DiseasesCancer
- First Posted Date
- 2010-08-12
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01180868
- Locations
- 🇺🇸
UCLA, Los Angeles, California, United States
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase 2
Completed
- Conditions
- Giant Cell GlioblastomaGlioblastomaGliosarcoma
- Interventions
- Other: laboratory biomarker analysisOther: immunohistochemistry staining methodGenetic: microarray analysisGenetic: DNA methylation analysis
- First Posted Date
- 2010-06-24
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT01149850
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸Kaiser Foundation Hospital, Los Angeles, California, United States
🇺🇸Kaiser Permanente at San Diego, San Diego, California, United States
Cellular Immunotherapy Study for Brain Cancer
Phase 1
Completed
- Conditions
- Anaplastic AstrocytomaGliomasAnaplastic OligodendrogliomaMalignant MeningiomaAnaplastic Mixed GliomaGlioblastoma Multiforme
- Interventions
- Drug: alloreactive CTL
- First Posted Date
- 2010-06-15
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 10
- Registration Number
- NCT01144247
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma
Phase 2
Withdrawn
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2010-02-17
- Last Posted Date
- 2012-07-31
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT01070186
Hypo-fractionated Stereotactic Body Radiotherapy for Localized Prostate Cancer
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2010-02-01
- Last Posted Date
- 2020-11-25
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 167
- Registration Number
- NCT01059513
- Locations
- 🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Stereotactic Body Radiotherapy and Radiofrequency Ablation for Lung Tumors Near Central Airways
Not Applicable
Completed
- Conditions
- Lung Cancer
- Interventions
- Radiation: Stereotactic Body RadiationRadiation: Radiofrequency Ablation
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT01051037
- Locations
- 🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Non-Metastatic, Post Menopausal Breast Cancer Patients
Completed
- Conditions
- Breast Cancer
- Interventions
- Other: History and Physical ExamOther: Grip Strength MeasurementBehavioral: SurveysOther: Blood CollectionProcedure: Ultrasound of Hand/Wrist
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2016-09-09
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 27
- Registration Number
- NCT01051609
- Locations
- 🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)
Phase 2
Terminated
- Conditions
- Metastatic Breast CancerLung Cancer
- Interventions
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2016-02-12
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT01029925
- Locations
- 🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase 2
Completed
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- First Posted Date
- 2009-11-13
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT01013285
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, University of California, Los Angeles (UCLA), Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath